OGEN ORAGENICS INC.

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA.

The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on CNS therapeutics, emergency-use treatments, and infectious disease applications. Dr. Kelly shared key insights on optimizing intranasal drug delivery, its advantages in neurological treatment, and Oragenics' approach to improving concussion patient outcomes.

Oragenics is advancing ONP-002, a novel neurosteroid designed to treat mild traumatic brain injury (mTBI) aka concussion, leveraging intranasal administration for rapid absorption and targeted brain delivery. The company’s participation in this summit underscores its commitment to innovation in non-invasive CNS therapeutics and sharing insights with the intranasal research community.

For more information about the 3rd Nasal Formulation & Delivery Summit, visit .

Investor Contact

Rich Cockrell

866.889.1972

tal

About Oragenics, Inc.

Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, for the treatment of mild traumatic brain injury (mTBI) or concussion. The Company is also advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration. For more information, visit .



EN
07/04/2025

Underlying

OGENORAGENICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ORAGENICS INC.

 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics Q2 2025 Shareholder Update

Oragenics Q2 2025 Shareholder Update Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering biotechnology company striving to develop brain-targeted therapeutics through proprietary intranasal delivery technology, today shared key strategic and financial milestones achieved during the second quarter of 2025 and shortly thereafter. These successes underscore the company's momentum as it strives to transform neurotrauma care and ...

August 11, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics Selects Southern Star Research as Clinical Research Organiza...

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion Study SARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for conc...

July 31, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to S...

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the trea...

July 16, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics Completes Approximately $16.5 Million Offering

Oragenics Completes Approximately $16.5 Million Offering Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury SARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The Company secured total gross proceeds of approximately $16.5 million. As part of the ...

July 2, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Mill...

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock ...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch